Insulin producers are shifting their focus to GLP-1s, a development that may have significant implications for the healthcare industry. This pivot is seen as a potential opportunity for growth and innovation, with some companies poised to benefit from the trend. The impact of this shift on the broader economy and job market is unclear, with other factors also influencing the outlook for various industries.